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Abstract
Background: This retrospective cohort study characterized the impact of prior antibiotic exposure on distribution
and nonsusceptibility profiles of Gram-negative pathogens causing hospital-onset urinary tract infections (UTI).
Methods: Hospital patients with positive urine culture for Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae,
and other Enterobacteriaceae ≥3 days after hospital admission were included. Assessment outcomes included the
distribution of bacteria in urine cultures, antibiotic susceptibility patterns, and the effect of prior antibiotic exposure, defined
as 0, 1, or ≥2 prior antibiotics, on the distribution and antibiotic susceptibility profiles of the Gram-negative organisms.
Results: The most commonly isolated pathogens from 5574 unique UTI episodes (2027 with and 3547 without prior
antibiotic exposure) were E. coli (49.5%), K. pneumoniae (17.1%), and P. aeruginosa (8.2%). P. aeruginosa was significantly
more commonly isolated in patients with ≥2 prior antibiotic exposures (12.6%) compared with no exposure (8.2%; p = 0.
036) or 1 prior exposure (7.9%; p = 0.025). Two or more prior antibiotic exposures were associated with slightly higher
incidences of fluoroquinolone nonsusceptibility, multidrug resistance, and extended-spectrum β-lactamase phenotype
compared with 0 or 1 exposure, suggesting an increased risk for resistant Gram-negative pathogens among hospital
patients with urinary tract infections occurring ≥3 days after admission.
Conclusions: Clinicians should critically assess prior antibiotic exposure when selecting empirical therapy for patients with
hospital-onset urinary tract infections caused by Gram-negative pathogens.
Keywords: Antibiotic use, Antimicrobial resistance, Fluoroquinolones, Gram-negative pathogens, Multidrug resistant,
Urinary tract infection
Background
Increasing antibiotic resistance among Gram-negative path-
ogens, particularly in the hospital setting, is well docu-
mented and constitutes a major public health concern [1, 2].
Gram-negative organisms are implicated in a number of
hospital-acquired infections, with urinary tract infections
(UTIs) particularly common [1, 3]. Antibiotic resistance
among hospital-acquired infections owing to Gram-negative
pathogens greatly complicates the administration of timely
and appropriate therapy, placing patients at increased risk
for deleterious outcomes [4–6]. Resources such as antibio-
grams can facilitate the empirical antimicrobial selection
process [7] by characterizing local resistance patterns.
However, reliance on a single collective isolate institutional
antibiogram for empirical antibiotic selection is associated
with several notable shortcomings. Collective isolate antibio-
grams developed by many institutions do not capture the
distribution of pathogens associated with a particular
infection, nor do they reflect the susceptibility profile of a
particular pathogen at an infection site (eg, urinary tract).
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Although culture site–specific antibiograms can amelior-
ate this issue, they do not indicate patient-specific factors
that increase the likelihood of an antibiotic-resistant
infection [7].
Two critical patient characteristics that modify the risk
for antibiotic-resistant infection are recent antibiotic
exposure and recent admission to, or current residence
in, a health care institution [2, 8, 9]. Considering the
limitations associated with an antibiogram-only ap-
proach to empirical antibiotic selection, this study was
designed to characterize the impact of prior antibiotic
exposure on the distribution and nonsusceptibility pro-
files of key Gram-negative pathogens among US inpa-
tients with hospital-onset UTIs. We specifically focused
on this single modifiable risk factor because it is readily
identifiable and accessible in the medical record system
for all patients. Other possible patient risk factors were
not included in the analysis so that a simple and
straightforward guide to empirical antibiotic selection
could be created.
Methods
Study design and population
This retrospective, observational study used hospital dis-
charge data from the Premier Healthcare Database,
which at the time of this study contained data from
more than 435 million patient encounters. Laboratory
results were available from a subset of approximately
160 facilities in the Premier Healthcare Database. Pa-
tients were included in the study if all the following cri-
teria were met: inpatient discharge between January 1,
2012, and March 31, 2013; positive urine culture for any
of the prespecified Gram-negative bacteria ≥3 days after
hospital admission; and receipt of an antibiotic with ac-
tivity against Gram-negative pathogens on the index cul-
ture date or within the 3-day period thereafter. The first
documented urine culture was included in the analysis.
Duplicate isolates from subsequent urine cultures within
30 days were excluded. Duplicate isolates recovered from
urine cultures >30 days after the index culture were in-
cluded because we felt these to be representative of ei-
ther recurrent or new infection. As such, we felt it was
important to include these subsequent occurrences as
unique episodes within the study.
The Gram-negative organisms of interest were Escheri-
chia coli, Klebsiella pneumoniae, Pseudomonas aerugi-
nosa, and other members of the Enterobacteriaceae
family (excluding E. coli and K. pneumoniae). Prior anti-
biotic exposure was defined as administration of ≥1 pre-
specified agents with Gram-negative activity during the
current hospitalization and before the index urine
culture. Antibiotics included for assessment of prior
exposure were those available in the working Premier
data set: meropenem, doripenem, imipenem, ertapenem,
piperacillin/tazobactam, cefepime, ceftazidime, ceftriax-
one, cefotaxime, ciprofloxacin, levofloxacin, gentamicin,
tobramycin, amikacin, ampicillin/sulbactam, cefazolin,
gatifloxacin, cefazolin, tigecycline, and ticarcillin/clavula-
nic acid (or clavulanate). Data for other groups of
antibiotics, including second-generation cephalosporins
and trimethoprim/sulfamethoxazole, were not available.
Outcomes
The first outcome measure was distribution and anti-
biotic susceptibility patterns among the prespecified
Gram-negative organisms for patients meeting inclusion
criteria. The second outcome measure was the associ-
ation of prior antibiotic exposure, defined as 0, 1, or ≥2
prior exposures, with the distribution and antibiotic
susceptibility profiles of the Gram-negative organisms of
interest. Organisms were assessed for susceptibility to
fluoroquinolones (ciprofloxacin, levofloxacin, gatifloxa-
cin), carbapenems (meropenem, imipenem, doripenem,
ertapenem), and piperacillin/tazobactam.
For the purposes of this analysis, antibiotic suscep-
tibility was classified as susceptible versus nonsusceptible
(ie, intermediate or resistant), based on the microbiology
report. Multidrug resistance was defined as non-
susceptibility to ≥1 agents in ≥3 antibiotic classes [10].
For P. aeruginosa, only meropenem-, imipenem-, or
doripenem-nonsusceptibility was used to define carba-
penem resistance; P. aeruginosa isolates were considered
nonsusceptible to third-generation cephalosporins if they
were resistant to ceftazidime, or, if data were unavailable,
to cefepime. For Enterobacteriaceae, isolates were consid-
ered nonsusceptible to a third-generation cephalosporin if
they had documented resistance to at least two agents
(ceftriaxone, ceftazidime, or cefotaxime). Nonsusceptibility
to third-generation cephalosporins was considered indica-
tive of an extended-spectrum beta-lacatmase (ESBL)
phenotype. For patients with missing carbapenem, pipera-
cillin/tazobactam, or MDR susceptibility data, isolates
were considered carbapenem-susceptible, piperacillin/taz-
obactam-susceptible, or non-MDR if they were susceptible
to a third-generation cephalosporin. Otherwise, carba-
penem, piperacillin/tazobactam, and MDR susceptibility
data were considered missing and were not included in
the analyses that evaluated the relationship between prior
antibiotic exposures and antibiotic susceptibility profiles.
Statistical analysis
Unadjusted descriptive analysis was used to characterize
the distribution and antibiotic susceptibility patterns of
the Gram-negative organisms of interest and the effect of
prior antibiotic exposure on each of these patterns.
Although the study was not powered for prespecified stat-
istical analyses, possible significance between groups (≥2
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prior exposures compared with 0 or 1 prior exposure) was
calculated using the method of Miettinen and Nurminen.
Results
Overall pathogen distribution and resistance profile
Descriptive statistics of patient demographics and charac-
teristics of hospital visits are provided (see Additional file
1). A total of 5574 unique UTI episodes were included in
the analysis (n = 2027 prior antibiotic exposure; n = 3547
no prior exposure), from which 6093 pathogens were
isolated (n = 2227 from patients with prior antibiotic
exposure; n = 3866 from patients with no prior exposure).
The most commonly isolated pathogens were E. coli (n =
3013; 49.5%), K. pneumoniae (n = 1039; 17.1%), and P.
aeruginosa (n = 502; 8.2%) (Fig. 1). Among all pathogens,
fluoroquinolone nonsusceptibility and multidrug resist-
ance exceeded 19 and 21%, respectively (Fig. 2). The ESBL
phenotype was noted in 4.1% of pathogens, and carba-
penem nonsusceptibility was noted in <2%.
Effect of prior antibiotic exposure
The distribution of pathogens in relation to prior anti-
biotic exposure is shown in Fig. 1. P. aeruginosa was
isolated significantly more often in patients with ≥2 prior
antibiotic exposures (12.6%) than in patients with no
prior antibiotic exposure (8.2%; 95% confidence intervals
[CI] 0.2, 10.1; p = 0.036) or with 1 prior exposure (7.9%;
95% CI 0.5, 10.5; p = 0.025). For other pathogen groups,
the presence or absence of prior antibiotic exposure did
not substantially affect distribution trends, and differ-
ences were nonsignificant.
Nonsusceptibility characteristics with respect to 0, 1,
or ≥2 prior antibiotic exposures are shown in Fig. 2 and
Table 1. Among all pathogens, a trend toward slightly
higher incidences of fluoroquinolone nonsusceptibility
and of multidrug-resistant and ESBL phenotypes wase
seen with ≥2 prior antibiotic exposures than with 1 or 0
(Fig. 2); however, with the exception of ESBL phenotype
in patients with ≥2 vs 1 prior antibiotic exposures (6.6%
vs 3.6%; 95% CI 0.1, 7.7; p = 0.041), these differences in
incidence were not statistically significant. This trend
seemed to be driven largely by susceptibility pattern
changes observed with K. pneumoniae (Table 1).
Discussion
The aim of this study was to characterize the distribu-
tion and antibiotic nonsusceptibility profiles of key
Gram-negative organisms by the presence of antibiotic
exposures among patients with hospital-onset UTIs.
Although numerous patient factors can affect pathogen
distribution and susceptibility trends, we focused on this
one risk factor given that it is modifiable and easily eval-
uated by clinicians using the medical record. Antibiotic
exposure is an important consideration given a recent
multicenter prevalence study describing antibiotic use in
50% of inpatients on any given day during admission
[11]. Therefore, our approach focusing on the number of
exposures offers a simple and straightforward supple-
ment to guide empirical antibiotic selection for hospital-
onset UTI treatment.
Our study focusing on the single risk factor of
antibiotic exposure produced several notable findings.
Consistent with epidemiologic trends, E. coli (49.5%)
was the most commonly isolated pathogen [8, 9, 12],
and this was consistent across all categories of prior
antibiotic exposure. Although the simple binary designa-
tion of prior antibiotic exposure did not seem to affect
overall pathogen distribution or nonsusceptibility trends,
Fig. 1 Pathogen distribution by prior antibiotic exposure
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differences became apparent on stratification by number
of exposures. Prior receipt of ≥2 antibiotic regimens was
associated with a significantly higher frequency of P.
aeruginosa UTIs and with slightly higher incidences of
fluoroquinolone-, carbapenem-, and third-generation
cephalosporin-nonsusceptibility as well as multidrug
resistance. Collectively, our findings suggest that previ-
ous exposure to ≥2 antibiotic regimens is associated with
an alteration of the distribution and susceptibility pro-
files of Gram-negative pathogens among patients with
hospital-onset UTIs.
Although antibiotic nonsusceptibility was highest among
those with ≥2 prior exposures to antibiotics, fluoroquino-
lone nonsusceptibility rates were >18%, even in the absence
of prior antibiotic exposure. This finding is not unexpected
given the large-scale use of fluoroquinolones for UTIs in
both community and health care settings. Emergence of re-
sistance to these antibiotics is recognized by a number of
world health agencies and is considered a major public
health concern [1, 2, 12]. Because practice guidelines rec-
ommend empirical use of fluoroquinolones for UTIs only if
local drug resistance rates do not exceed 10% [12], our find-
ings suggest that caution should be exercised with empirical
use of fluoroquinolones for hospital-onset UTIs, and strong
consideration should be given to alternative therapies with
broad-spectrum, Gram-negative coverage empirically.
Our findings also highlight the limitations associated with
relying solely on antibiograms for patients with hospital-
onset UTI, particularly those with ≥2 antibiotic exposures.
Although antibiograms are a useful starting point in the
empirical drug selection process, they reflect the cumulative
susceptibility rates for the first recovered pathogen in a
particular patient, regardless of current site, timing of col-
lection (community vs hospital onset), or patient-specific
risk factors for resistance (eg, prior exposure to antibiotics)
[7]. Recent guidelines from the Infectious Diseases Society
of America and the Society for Hospital Epidemiology of
America acknowledge several of these limitations and en-
courage the development of enhanced antibiograms strati-
fied by various parameters (eg, age, location within the
institution, infection site, patient comorbidities, and site of
acquisition) to improve empirical selection of antibiotics.
Furthermore, these guidelines encourage the development
of institution-specific clinical treatment guidelines for com-
mon infectious diseases [13]. Our findings that prior anti-
biotic exposure alters the distribution of pathogens and the
susceptibility profiles of common Gram-negative organisms
implicated in UTIs occurring ≥3 days after admission can
easily be incorporated into clinical treatment guidelines to
promote a more patient-specific approach to timely selec-
tion of appropriate empirical antibiotic therapy. In addition
to guiding the selection of appropriately broad-spectrum
empirical therapy for hospital-onset UTI, our findings
may be helpful to institutional antimicrobial stewardship
programs to target antibiotics likely to be inappropriate
(eg, fluoroquinolones).
Some limitations should be considered when interpret-
ing these findings. First, though we acknowledge that
several factors may contribute to antibiotic-resistant
infections, we purposefully did not assess multiple risk
factors because data were not uniformly available for all
patients. We also believed that inclusion of other patient
factors would complicate our intent to create a simple,
straightforward approach to guide empirical antibiotic
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Fig. 2 Antibiotic nonsusceptibility phenotypes across all pathogens by prior antibiotic exposure. MDR multidrug resistant; NS nonsusceptible
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selection. Because we did not adjust for other factors,
our findings cannot substantiate prior use of antibiotics
as an independent risk factor for, or as a cause of,
resistance, but our findings do show that prior use is an
additional easily identifiable variable that can be used to
guide empirical therapy. Second, the study was restricted
to patients with UTIs occurring ≥3 days after hospital
admission. Although we had access to detailed
hospitalization data, information on antibiotic and
health care exposure before admission was limited. As
such, we focused on patients for whom complete,
detailed data were available. The 3-day time frame after
hospital admission fails to account for recent antibiotic
use in outpatient or other institutional settings; there-
fore, the potential effects of these exposures on our find-
ings are unknown. Third, this study did not specifically
quantify the relationship between cumulative duration of
exposure to all or any given antibiotic and the presence
of resistance. Given that the goal of the study was to
provide clinicians with a straightforward, easily adapt-
able method for empirical antibiotic selection, we did
not think it was necessary to specify with increased
granularity the relationship between duration of prior
antibiotic exposure and resistance. Although we were
able to document prior receipt of many commonly used
antibiotics with Gram-negative activity, data for other
groups of antibiotics, including second-generation ceph-
alosporins, and trimethoprim/sulfamethoxazole, were
not available for this analysis. The relatively small
number of patients with ≥2 prior antibiotic exposures
might also limit the interpretation of findings regarding
resistance, though increased rates observed among fewer
pathogens is still of concern. In addition, though the
statistical analysis suggests some significant differences
Table 1 Nonsusceptibility phenotypes by prior antibiotic exposure




Escherichia coli (n = 3013)a,b Fluoroquinolone-NS 25.4 (758/2990) 25.5 (482/1888) 24.8 (253/1020) 28.0 (23/82)
Third-generation cephalosporin-NS 3.5 (105/3013) 3.8 (72/1903) 2.7 (28/1028) 6.1 (5/82)
MDR 23.4 (705/3013) 24.1 (458/1903) 21.6 (222/1028) 30.5 (25/82)
Carbapenem-NS 0.1 (4/3006) 0.2 (3/1900) 0.1 (1/1025) 0 (0/81)
Piperacillin/tazobactam-NS 4.4 (131/2965) 4.6 (86/1871) 4.1 (42/1014) 3.8 (3/80)
Klebsiella pneumoniae (n = 1039)a,c Fluoroquinolone-NS 6.8 (70/1036) 6.0 (41/689) 7.5 (24/320) 18.5 (5/27)
Third-generation cephalosporin-NS 3.7 (38/1039) 2.7 (19/692) 5.0 (16/320) 11.1 (3/27)
MDR 10.1 (105/1039) 9.2 (64/692) 11.3 (36/320) 18.5(5/27)
Carbapenem-NS 1.5 (16/1035) 1.0 (7/690) 2.5 (8/319) 3.8 (1/26)
Piperacillin/tazobactam-NS 7.1 (73/1021) 6.0 (41/685) 9.4 (29/310) 11.5 (3/26)
Pseudomonas aeruginosa (n = 502)a,d Fluoroquinolone-NS 21.8 (109/499) 22.2 (70/316) 20.6 (33/160) 26.1 (6/23)
Third-generation cephalosporin-NS 8.8 (44/502) 10.4 (33/318) 5.0 (8/161) 13.0 (3/23)
MDR 8.8 (44/502) 10.4 (33/318) 5.0 (8/161) 13.0 (3/23)
Carbapenem-NS 7.3 (36/496) 7.3 (23/314) 5.7 (9/159) 17.4 (4/23)
Piperacillin/tazobactam-NS 4.0 (20/494) 4.1 (13/314) 4.4 (7/158) 0 (0/22)
Other Enterobacteriaceae (n = 1539)a,e Fluoroquinolone-NS 14.1 (216/1531) 14.5 (137/947) 13.9 (74/534) 10.0 (5/50)
Third-generation cephalosporin-NS 3.9 (60/1539) 4.0 (38/953) 3.9 (21/536) 2.0 (1/50)
MDR 27.6 (424/1539) 26.4 (252/953) 29.9 (160/536) 24.0 (12/50)
Carbapenem-NS 1.5 (23/1525) 1.5 (14/944) 1.7 (9/532) 0 (0/49)
Piperacillin/tazobactam-NS 4.9 (75/1529) 4.8 (45/947) 5.4 (29/533) 2.0 (1/49)
MDR multidrug resistant, n number of nonsusceptible isolates, N total number of isolates, NS nonsusceptible
aFor patients with missing susceptibility data, isolates were considered to be carbapenem-susceptible, piperacillin/tazobactam-susceptible, or non-MDR if they
were susceptible to a third-generation cephalosporin. Otherwise, carbapenem, piperacillin/tazobactam, and MDR susceptibility data were considered missing, and
isolates were not included in the analyses
bE. coli: 903 isolates were missing carbapenem susceptibility data, of which 896 were classified according to the rules described above and seven were excluded
from the analysis due to missing data; 1412 isolates were missing piperacillin/tazobactam susceptibility data, of which 1364 were classified according to the rules
and 48 were excluded
cK. pneumoniae: 317 isolates were missing carbapenem susceptibility data, of which 313 were classified according to the rules and four were excluded; 443
isolates were missing piperacillin/tazobactam susceptibility data, of which 425 were classified according to the rules and 18 were excluded
dP. aeruginosa: 97 isolates were missing carbapenem susceptibility data, of which 91 were classified according to the rules and six were excluded; 109 isolates
were missing piperacillin/tazobactam susceptibility data, of which 101 were classified according to the rules and eight were excluded
eOther Enterobacteriaceae: 494 isolates were missing carbapenem susceptibility data, of which 480 were classified according to the rules and 14 were excluded;
721 isolates were missing piperacillin/tazobactam susceptibility data, of which 711 were classified according to the rules and ten were excluded
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between patients with ≥2 prior exposures and patients
with 0 or 1 prior exposure, it should be noted that the
numbers of patients in some of the groups were very
small. As such, determination of the true statistical
relevance of prior antibiotic exposure will require add-
itional studies adequately powered to determine signifi-
cance levels. Fourth, given that the presence of the ESBL
phenotype among pathogens was not formally tested,
the use of select third-generation cephalosporin resist-
ance as a marker for ESBL may underestimate or
overestimate the true incidence of ESBL. However, we
believe third-generation cephalosporin resistance repre-
sented a practical surrogate because it is readily available
to clinicians on urine culture susceptibility reports and
that routine formal ESBL testing is not recommended by
the Clinical and Laboratory Standards Institute (CLSI).
Furthermore, given that culture susceptibility reports
were from clinical and not reference laboratories, it can
be assumed that third-generation cephalosporin resist-
ance was reported using the US Food and Drug Admin-
istration–approved minimum inhibitory concentration
breakpoint, which may better correlate with the presence
of ESBL than CLSI breakpoints [14]. Finally, because
findings are derived from positive urine cultures in the
absence of a complete clinical picture, it is difficult to
definitively distinguish between true infections and
colonization. However, all patients received an antibiotic
in response to a positive urine culture, which is suggest-
ive of symptomatic infection for most patients.
Conclusions
Having received ≥2 prior antibiotic regimens was associ-
ated with increased risk for a resistant Gram-negative
pathogen among patients with hospital-onset UTIs. In
addition to considering the hospital antibiogram, which
should be stratified for greater usefulness, hospital clini-
cians should critically assess prior exposure to antibi-
otics when selecting empirical therapy for patients with
UTIs that occur ≥3 days after admission. Awareness of
common pathogen distribution and nonsusceptibility
trends among hospital patients with UTIs, combined
with readily identifiable patient risk factors for infection
with resistant pathogens, can provide a useful framework
for clinicians during the empirical antibiotic selection
process.
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